269071-41-2Relevant academic research and scientific papers
Optimization of the in vitro and in vivo properties of a novel series of 2,4,5-trisubstituted imidazoles as potent cholecystokinin-2 (CCK2) antagonists
Buck, Ildiko M.,Black, James W.,Cooke, Tracey,Dunstone, David J.,Gaffen, John D.,Griffin, Eric P.,Harper, Elaine A.,Hull, Robert A. D.,Kalindjian, S. Barret,Lilley, Elliot J.,Linney, Ian D.,Low, Caroline M. R.,McDonald, Iain M.,Pether, Michael J.,Roberts, Sonia P.,Shankley, Nigel P.,Shaxted, Mark E.,Steel, Katherine I. M.,Sykes, David A.,Tozer, Matthew J.,Watt, Gillian F.,Walker, Martin K.,Wright, Laurence,Wright, Paul T.
, p. 6803 - 6812 (2007/10/03)
The systematic optimization of the structure of a novel 2,4,5-trisubstituted imidazole-based cholecystokinin-2 (CCK2) receptor antagonist afforded analogues with nanomolar receptor affinity. These compounds were now comparable in their potency
Gastrin and cholecystokinin receptor ligands (III)
-
, (2008/06/13)
Compounds of formula (I) and their pharmaceutically acceptable salts are ligands at gastrin and/or cholecystokinin receptors. X and Y are independently ═N—, —N(R5)—(R5 being selected from H, Me, Et, Pr, Bn, OH and —CH2COOR
Pharmaceutical compositions comprising proton pump inhibitors and gastrin/cholecystokinin receptor ligands
-
, (2008/06/13)
Pharmaceutical compositions comprising a proton pump inhibitor and a compound of the formula (I) or its pharmaceutically acceptable salts, are useful in treating gastrointestinal disorders. X and Y are independently ═N—, —N(R5)— (R5
Gastrin and cholecystokinin receptor ligands(II)
-
, (2008/06/13)
Substituted imidazoles (1) are useful as angiotensin II blockers. These compounds have activity in treating hypertension and congestive heart failure. Pharmaceutical compositions containing the novel imidazoles and pharmaceutical methods using them, alone and in conjunction with other drugs, especially diuretics and non-steroidal antiinflammatory drugs (NSAID's) are also described.
Gastrin and cholecystokinin receptor ligands
-
, (2008/06/13)
Compounds of formula (I) and their pharmaceutically acceptable salts are ligands at gastrin and/or cholecystokinin receptors. X and Y are independently ═N—, —N(R5)—═CH—, —S— or —O—. n is from 1 to 4; R1is H or C1to C1
